Investor Relations

The Leader in Brachytherapy

Isoray advances innovative radiotherapeutic technologies that focus on the patient.

Latest Results

Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...

Isoray Announces Second Quarter Fiscal 2020 Financial Results

Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...

Isoray Announces Record First Quarter Fiscal 2020 Financial Results

Record Revenue and Gross Profit Revenue Increased 48% Year-Over-Year  RICHLAND, WASHINGTON – November 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

Dawson James Securities Inc.
Jason Kolbert

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Investor Relations:

Mark Levin
Global IR Group
mark@globalirgroup.com

 

Our Management Team

Learn more about our experienced management team who are focused on growth.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.